rabbit anti cd44  (Boster Bio)

Journal: Journal of Nanobiotechnology

Article Title: Low-dose X-ray-activated radiodynamic therapy via a lutetium-coordinated nanoplatform synergizing PARP inhibition and ferroptosis

doi: 10.1186/s12951-026-04027-8

Figure Lengend Snippet: Physicochemical characterization, stability, and drug release profile of BPNS@Lu 3+ /Lap-CMV. (a) Hydrodynamic size distribution of BPNS@Lu 3+ /Lap-CMV. (b) Zeta potential of BPNS, BPNS@Lu 3+ , BPNS@Lu 3+ /Lap, CMV, and BPNS@Lu 3+ /Lap-CMV ( n = 3). (c) UV–vis absorption spectra of Lap, BPNS/Lap, BPNS@Lu 3+ /Lap-CMV and BPNS. (d) Raman scattering spectra of BPNS, BPNS@Lu 3+ /Lap, BPNS@Lu 3+ /Lap-CMV. (e) Full-survey XPS spectrum and (f) high-resolution Lu 4 d XPS spectrum of BPNS@Lu 3+ /Lap-CMV. (g) Western blot analysis of the membrane marker CD44 and the nuclear protein histone H1t in (1) 4T1 cells, (2) CMs, (3) CMV, (4) BPNS@Lu 3+ /Lap, and (5) BPNS@Lu 3+ /Lap-CMV. (h) Protein concentration of CMV and BPNS@Lu 3+ /Lap-CMV by BCA assay. (i) CLSM images of cellular uptake of BPNS@Lu 3+ /Lap-CMV. Cy5 (red) represents the BPNS@Lu 3+ /Lap core, DiO (green) represents the tumor membrane shell, and DAPI (blue) stains the cell nuclei. (j) TEM images and elemental mapping images of BPNS, BPNS@Lu 3+ , BPNS@Lu 3+ /Lap, and BPNS@Lu 3+ /Lap-CMV (scale bar = 200 nm). (k) Colloidal stability of bare BPNS and (l) BPNS@Lu 3+ /Lap in aqueous solution over a 9-day period. (m) Cumulative release profiles of Lu 3+ and (n) Lap from BPNS@Lu 3+ /Lap-CMV under physiological (pH 7.4), acidic (pH6.0, pH 4.8), and chelating (with EDTA) conditions over 96 h (n = 3). Data are presented as mean ± standard deviation

Article Snippet: Rabbit anti-H1t antibody (catalog No. bs-1413R), and Rabbit anti-CD44 antibody (catalog No. bs-4916R) were purchased from Bioss (Beijing, China).

Techniques: Zeta Potential Analyzer, Western Blot, Membrane, Marker, Protein Concentration, BIA-KA, Standard Deviation

Journal: iScience

Article Title: pH-responsive CaCO 3 nanoplatform amplifies SDT via calcium overload-ROS loop for deep tumor therapy

doi: 10.1016/j.isci.2026.115082

Figure Lengend Snippet: Synthesis process and mechanism diagram of HA/CaCO 3 @Ce6 (A) Schematic of the functional pattern of HA/CaCO 3 @Ce6. (B) Tumor microenvironment-responsive calcium-based nanoplatform enables CD44-targeted modulation, improves acidic tumor niche, and amplifies mitochondrial Ca 2+ overload-mediated ROS production to trigger immunogenic cell death, thereby potentiating SDT efficacy.

Article Snippet: Anti-Mouse CD44 Rabbit Recombinant Antibody , Sanying Biotechnology , Cat No. 15675-1-AP; RRID: AB_2076198.

Techniques: Functional Assay

Journal: iScience

Article Title: pH-responsive CaCO 3 nanoplatform amplifies SDT via calcium overload-ROS loop for deep tumor therapy

doi: 10.1016/j.isci.2026.115082

Figure Lengend Snippet: In vitro HA-mediated targeting performance and the antitumor effects of HA/CaCO 3 @Ce6 (A) Flow cytometry analysis of CD44 receptor expression on the membrane surface of the different liver cancer cells. (B) Quantitative analysis of CD44 receptor expression on the membrane surface of the different liver cancer cells. Data are expressed as the mean ± SD ( n = 3), ∗∗∗p < 0.001 by Student’s t test. (C) CLSM images of Hepa1-6 cells stained with Fluo-4 after incubations with PBS, CaCO 3 , CaCO 3 @Ce6, and HA/CaCO 3 @Ce6 for 6 h. Scale bars, 100 μm. (D) Quantitative analysis of fluorescence intensity of Hepa1-6 cells stained with Fluo-4 after incubations with PBS, CaCO 3 , CaCO 3 @Ce6, and HA/CaCO 3 @Ce6 (G1–G4) for 6 h, respectively. Data are expressed as the mean ± SD ( n = 3). ∗∗∗p < 0.001 by Student’s t test. (E) Cell viability of Hepa1-6 cells treated with PBS, CaCO 3 , CaCO 3 @Ce6, and HA/CaCO 3 @Ce6 with different concentrations for 24 h. Data are expressed as the mean ± SD ( n = 3). ∗∗∗p < 0.001 by Student’s t test. (F) Cell viability of Hepa1-6 cells incubated with PBS, CaCO 3 , CaCO 3 @Ce6, and HA/CaCO 3 @Ce6 for 6 h and irradiated with different US intensity for 3 min. Data are expressed as the mean ± SD ( n = 3), ∗∗∗p < 0.001 by Student’s t test. (G) FCM patterns of apoptotic cells in Hepa1-6 cells with different treatments. (H) Quantitative analysis of apoptotic cells in Hepa1-6 cells with different treatments. G1–G6 represent PBS, CaCO 3 , CaCO 3 @Ce6, CaCO 3 @Ce6 + US, HA/CaCO 3 @Ce6 + US, and Ce6 + US, respectively. Data are expressed as the mean ± SD ( n = 3), ∗∗p ˂ 0.05; ∗∗∗p < 0.001 by Student’s t test. CLSM, confocal laser scanning microscopy; US, ultrasound.

Article Snippet: Anti-Mouse CD44 Rabbit Recombinant Antibody , Sanying Biotechnology , Cat No. 15675-1-AP; RRID: AB_2076198.

Techniques: In Vitro, Flow Cytometry, Expressing, Membrane, Staining, Fluorescence, Incubation, Irradiation, Confocal Laser Scanning Microscopy

Journal: Stroke

Article Title: Trametinib decreased intracerebral hemorrhages and endothelial-to-mesenchymal transition in KRAS G12V -induced brain arteriovenous malformations in mice

doi: 10.1161/STROKEAHA.125.052418

Figure Lengend Snippet: (A) Immunostaining images of mesenchymal markers (N-cad, Slug, and CD44), endothelial marker (VE-Cad), (B) proliferation (Ki-67), and angiogenesis markers (CD34 and pVEGFR2), and the respective intensity in CD31+ intact and bAVM vessels. n=ROIs (dots) in 2–3 (Veh) or 3–6 (TM) mice (1mg/kg and 2mg/kg combined), Mice were sacrificed at 10 weeks after treatments, Data expressed as mean value of dots ± SEM, * p <0.05, ** p <0.01, *** p <0.001, **** p <0.0001 vs KRAS G12V mice treated with vehicle. Student’s t -test. Scale bar = 100μm. Veh, Vehicle; TM, Trametinib.

Article Snippet: The fixed samples were incubated with primary antibodies: CD31 (AF3628, R&D Systems, Minneapolis, MN), Ter119 (MAB1125, R&D systems), VE-Cad (361900, Thermo Fisher Scientific, Waltham, MA), p-ERK1/2 (9101S), N-Cad (13116S), Slug (9585S), CD44 (37259S), and Ki-67 (9129S) from Cell Signaling Technology, CD34 (NB6001071, Novus Biologicals, Centennial, CO), or pVEGFR2 (SAB4504567, Sigma-Aldrich, St. Louis, MO), followed by secondary antibodies: 488-conjugated donkey anti-goat (705-545-147) or anti-rabbit IgG (711-545-152), Rhodamine Red-X-AffiniPure donkey anti-mouse (715-295-151), anti-rabbit (711-295-152), or anti-goat IgG (705-295-147), 647-conjugated donkey anti-rabbit (711-605-152), anti-mouse (715-605-150), or anti-rat IgG (712-605-153).

Techniques: Immunostaining, Marker

Journal: British Journal of Cancer

Article Title: CD44 upregulation in chronic liver disease marks the transition to hepatocellular carcinoma and portends poor prognosis

doi: 10.1038/s41416-025-03284-y

Figure Lengend Snippet: a Representative images of CD44 IHC in injury model livers (arrows indicate CD44-positive hepatocytes). b CD44v6 IHC in injury models (arrows indicate CD44v6-positive hepatocytes or cholangiocytes). c Quantification of CD44 and ( d ) CD44v6 expression based on integrated optical density (IOD) in the indicated liver injury models. e Representative images of liver sections from CCl 4 -treated mice at 4 weeks and 16 weeks, as well as an HCC. H&E staining, Sirius Red staining (fibrosis in red), and CD44 IHC (red arrows point to CD44-positive hepatocytes) are shown. f Quantification of CD44-positive hepatocytes in CCl 4 -treated mice over time. *= p < 0.05; **= p < 0.01.

Article Snippet: After blocking with 10% normal goat or rabbit serum containing 3% BSA in TBST, sections were incubated overnight at 4 °C with three sets of primary antibodies for co-staining: CD44 (#37259, Cell Signaling, 1:200) together with FOXP3 (#14-4771-80, ThermoFisher, 1:200), CD44 (IM7, #14-0441-82, ThermoFisher, 1:400) together with F4/80 (#70076, Cell Signaling, 1:200) and CD44 (#37259, Cell Signaling, 1:200) together with CD206 (#PA5-46994, ThermoFisher, 1:200).

Techniques: Expressing, Staining

Journal: British Journal of Cancer

Article Title: CD44 upregulation in chronic liver disease marks the transition to hepatocellular carcinoma and portends poor prognosis

doi: 10.1038/s41416-025-03284-y

Figure Lengend Snippet: a CD44 mRNA expression (TPM) in TCGA HCC tumours vs. adjacent normal liver (NTL). b CD44 mRNA levels by tumour stage (TCGA HCC). c Representative immunohistochemistry images of normal liver, adjacent non-tumorous liver, HCC, and iCCA tissues (images retrieved from the Human Protein Atlas). d Kaplan–Meier overall survival curves for TCGA HCC patients with CD44 high vs. CD44 low tumours. e Validation of survival difference in CD44 high vs. CD44 low groups using GEPIA2 (combined TCGA/GTEx data). ****= p < 0.0001.

Article Snippet: After blocking with 10% normal goat or rabbit serum containing 3% BSA in TBST, sections were incubated overnight at 4 °C with three sets of primary antibodies for co-staining: CD44 (#37259, Cell Signaling, 1:200) together with FOXP3 (#14-4771-80, ThermoFisher, 1:200), CD44 (IM7, #14-0441-82, ThermoFisher, 1:400) together with F4/80 (#70076, Cell Signaling, 1:200) and CD44 (#37259, Cell Signaling, 1:200) together with CD206 (#PA5-46994, ThermoFisher, 1:200).

Techniques: Expressing, Immunohistochemistry, Biomarker Discovery

Journal: British Journal of Cancer

Article Title: CD44 upregulation in chronic liver disease marks the transition to hepatocellular carcinoma and portends poor prognosis

doi: 10.1038/s41416-025-03284-y

Figure Lengend Snippet: a Volcano plot of differentially expressed genes in CD44 high vs. CD44 low HCC (red dots = upregulated genes; green dots = downregulated genes; selected genes labelled). b Top KEGG pathways enriched in CD44 high tumours (bar graph of -log 10 P values). c GSVA enrichment scores for selected oncogenic pathways (IL6/JAK/STAT3, TNFα/NF-κB, EMT, etc.) in CD44 high vs. CD44 low tumours. d Immune cell fraction comparison (xCell analysis) showing higher M2 macrophage and Th2 cell signatures in CD44 high tumours. *= p < 0.05; **= p < 0.01; ***= p < 0.001, ****= p < 0.0001.

Article Snippet: After blocking with 10% normal goat or rabbit serum containing 3% BSA in TBST, sections were incubated overnight at 4 °C with three sets of primary antibodies for co-staining: CD44 (#37259, Cell Signaling, 1:200) together with FOXP3 (#14-4771-80, ThermoFisher, 1:200), CD44 (IM7, #14-0441-82, ThermoFisher, 1:400) together with F4/80 (#70076, Cell Signaling, 1:200) and CD44 (#37259, Cell Signaling, 1:200) together with CD206 (#PA5-46994, ThermoFisher, 1:200).

Techniques: Comparison

Journal: British Journal of Cancer

Article Title: CD44 upregulation in chronic liver disease marks the transition to hepatocellular carcinoma and portends poor prognosis

doi: 10.1038/s41416-025-03284-y

Figure Lengend Snippet: UMAP plots of HCC ( a ) and iCCA ( d ) tumours derived from the single-cell RNA-seq datasets GSE166635 (HCC) and GSE138709 (iCCA), with major cell populations annotated (macrophages, T cells, and malignant cells). Feature plots showing CD44 expression levels across specific cell populations in HCC ( b ) and iCCA ( e ) samples (blue = high expression, grey = low expression). UMAP clustering of normal tissues (blue) versus tumour cells (orange) in an HCC sample ( c ) and an iCCA sample ( f ).

Article Snippet: After blocking with 10% normal goat or rabbit serum containing 3% BSA in TBST, sections were incubated overnight at 4 °C with three sets of primary antibodies for co-staining: CD44 (#37259, Cell Signaling, 1:200) together with FOXP3 (#14-4771-80, ThermoFisher, 1:200), CD44 (IM7, #14-0441-82, ThermoFisher, 1:400) together with F4/80 (#70076, Cell Signaling, 1:200) and CD44 (#37259, Cell Signaling, 1:200) together with CD206 (#PA5-46994, ThermoFisher, 1:200).

Techniques: Derivative Assay, RNA Sequencing, Expressing